tbuckley/cabot-search huggingface dataset:
Status of hypoglycemic medication in patients with type 2 diabetes mellitus in Beijing Chaoyang District
Authors: Bin Li
Journal: BMJ (2019)

One thousand and forty-six patients with type 2 diabetes mellitus (T2DM) aged >18 years from 11 community health service centers in Beijing Chaoyang district were enrolled in the study. The body weight, height, fasting plasma glucose level and glycosylated hemoglobin A1c (HbAlc) were measured. A door-to-door questionnaire survey on the use of oral antidiabetic drugs and insulin was conducted between January to December 2017. Of 1 046 T2DM patients, 182 (17.4%) received lifestyle intervention, 257 (24.6%) used single oral antidiabetic drug (OAD), 326 (31.2%) with combined OAD, and 281(26.9%) with insulin and OAD. The average HbA1c in T2DM patients with lifestyle intervention, single OAD drug, combined OAD, and insulin and OAD were (8.1±2.3)%, (7.6±2.0)%, (7.8±2.0)%, and (8.7±2.1)%, respectively (F=18.35, P<0.01). Proportions of the T2DM patients with HbAlc lower than 7.0% were 45.1%, 55.6%, 43.6% and 36.8% in groups, respectively (χ2=55.55, P<0.01). Patients with single or combined OAD aged 18-<45 years had a worse HbA1c control than those aged 45-<65 years and≥65 years. It was found that 59.4%, 52.6%and 30.8%of the patients receiving one OAD, two OADs and three or more OADs achieved glucose control target. The proportion of drug use was 62.6% for α-glucosidase inhibitors, 50.8% for metfomain, 32.5% for insulin, 18.2% for sulfonylureas, 4.9% for glinides, 3.2% for thiazolidinediones and 3.1% for dipeptidyl peptidase-Ⅳs. Among the combined treatment regimens, metfomain+a-glucosidase inhibitors was the most frequently used as compared with α-glucosidase inhibitors+sulfonylureas and metfomain+sulfonylureas. The survey showed that the target-reaching rate of HbA1c was 44.9%, and α-glucosidase inhibitors were frequently used for patients with T2DM in community health service centers in Beijing Chaoyang district south medical alliance.


Key words: 
Diabetes mellitus, type 2; Oral antidiabetic drug; Iinsulin; Lifestyle intervention
Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells.
Authors: David Edward Gilham, Simon Bornschein, Lorraine Springuel, Alexandre Michaux, Mikhail Steklov, Eytan Breman, Panagiota A Sotiropoulou
Journal: Journal of Clinical Oncology (2020)

3103 Background: Engineered T cells expressing chimeric antigen receptors (CAR) are now delivering clinically relevant results in patients with advanced hematological malignancies. One critical area for future development is to modulate gene expression thereby endowing the engineered T cell with specific desired features that enhance anti-tumor activity. Methods: Short-hairpin RNA (shRNA) were cloned individually or multiplexed within micro-RNA scaffolds that enabled the co-expression of the individual shRNA with a CAR and a selectable marker all driven by a PolII promoter within a single retroviral vector. Primary human T cells transduced with the CAR-shRNA vectors were selected, expanded in vitro, subjected to negative selection to eliminate any remaining TCR + cells and examined for target gene expression and functional activity. Results: A 500bp DNA fragment incorporating a shRNA-specific for CD3ζ cloned into a retroviral vectoreffectively knocked down expression of CD3ζ in transduced BCMA-specific CAR T cells. The consequent reduction of cell surface TCR expression resulted in minimal cytokine production upon TCR stimulation in vitro providing a potential allogeneic CAR T approach. These CAR T cells showed no demonstrable evidence of GvHD induction when infused in NSG mice yet maintained BCMA-specific CAR activity in KMS-11 and RPMI-8226 established myeloma models. Initial studies further confirmed that two shRNA could be expressed from a single retroviral vector to modulate the expression of multiple genes. Further engineering of the microRNA framework reduced the size of the transgene load to 394bp while enabling the expression of up to 4 shRNA within a single vector. shRNA specific for CD3ζ, beta-2-microglobulin, CD52 and diacylglycerol kinase alpha were engineered into the framework downstream of a CD19-CAR. Transduced Jurkat cells showed concurrent knockdown of the respective gene products at the mRNA and protein levels. Conclusions: A first-in-human clinical trial evaluating the first-generation single shRNA-vector in the context of a BCMA-targeting CAR as a non-gene edited approach to allogeneic CAR T cell therapy will be initiated in 2020. The proof of principle study here shows that multiple shRNAs are active within a single viral vector thereby avoiding the need for bespoke individual clinical reagents to target multiple genes. The multiplexed shRNA vector system is now in further development to explore whether this strategy can enhance the therapeutic potential of CAR T cells.
Dorsal ligament reconstruction for old dorsal dislocation of distal radioulnar joint
Authors: Jingning Li, Yuan Ji, Shengjun Yu, Fei Gao, Benjun Bi
Journal: BMJ (2015)

Objective
To evaluate the efficacy and safety of dorsal ligament reconstruction in treatment of old dorsal dislocation of distal radioulnar joint.


Methods
Seven patients with old dorsal dislocation of distal radioulnar joint were treated with dorsal ligament reconstruction using the palmaris longus tendon from March 2005 to May 2012 in our institute, including 4 males and 3 females with a mean age of 37 years. All patients had a history of wrist injury for more than 3 months and were diagnosed as isolated dislocation of distal radioulnar joint without fractures. During the operation a bone tunnel was made at dorsal ulnar side of radius near the ulnar notch, which was parallelized to long axial of ulna, two holes were drilled from dorsal to palmarulnaris side through the extensor carpi ulnaris sulcus of the ulna. The palmaris longus tendon was harvested and the strip of the tendon was penetrated through the radial hole. After the tips being crossed, put them through the holes of ulna, reduct the distal radioulnar joint by supinating the forearm, the strip of the tendon was sutured after being tightened, the reversed back the free end of the tendon to reconstruct the sheath of extensor carpi ulnaris tendon. Postoperatively, the upper extremity were kept in a long arm plaster in the position of elbow flexion 90° and forearm supination for 3 weeks, then the below elbow cast was replaced for another 3 weeks.


Results
Patients were followed-up for 1 year and 8 months-4 years and 2 months with the average of 2 years and 9 months. The rotation of wrist was improved and the handgrip strength was increased significantly. A functional evaluation was performed using the modified Mayo wrist scoring system. All patients had better wrists scores postoperatively(mean, 93) compared to preoperatively(mean, 68). All patients satisfied with the final result.


Conclusion
Dorsal ligament reconstruction should be a promise surgical modality for the old dorsal dislocation of distal radioulnar joint.


Key words: 
Carpal joints, ulnoradial; Dislocations, dorsal; Ligament reconstruction
Survey on the capacity and training needs of community mentors of general practice in different areas of Shanghai
Authors: Huiling Xia, Sunfang Jiang, Juan Shou, Shanzhu Zhu
Journal: BMJ (2015)

Objective
To investigate the capacity and training needs of the community general practice mentors in different areas of Shanghai.


Methods
General practice mentors from community health centers, who attended a municipal training program in Shanghai during July 2012 to October 2012, were participated in the survey with a self-designed questionnaire. The general condition, basic ability (clinical skill, teaching ability and professional development), motivation and needs of training were investigated. The factors affecting the willingness of training were analyzed.


Results
Among 742 mentors receiving the survey, 259 were from the urban area, 174 from rural-urban continuum and 309 from rural area. The academic degree in urban group was relatively higher: 17 out of 257 (6.6%) holding master degree. The ratio of participants who had received standardized training in urban, rural-urban and rural areas was 33.2%, 25.3%, 37.4%, respectively. The personal quality and communication skills in urban group were significantly higher than those in rural-urban continuum and rural group (18.58±2.49, 17.89±2.69, 17.85±2.34, P<0.05). The clinical skill (12.31±1.98, 11.95±2.02, 11.52±1.81), teaching ability (11.99±2.62, 11.63±2.86, 11.12±2.77) and professional development (6.42±1.61, 6.36±1.55, 5.61±1.38) in urban group were all significantly poorer than those in other two groups. The main purpose of participation in training was to improve medical knowledge and clinical skills in three groups(70.8%, 74.0%, 80.4%, respectively), followed by the need for community teaching. The rural group has higher training requirements in improving clinical diagnosis and treatment ability (75.3%, 80.1%, 85.5%, respectively in three groups), doctor-patient communication ability (38.0%, 44.0%, 50.7%, respectively) and community preventive care ability (29.4%, 30.7%, 42.8%, respectively). The urban group had much more requirements in scientific research training (38.8%, 34.9%, 14.1%, respectively). Logistic regression analysis showed that doctors with supports from the leadership (OR=2.688, P<0.05) and with less working stress (OR=2.241, P<0.05) were more willing to participate in mentor training.


Conclusion
There are discrepancies in basic ability and training needs of community general practice mentors in different areas of Shanghai, so we should develop specific or targeted training program in the future.


Key words: 
Teacher training; Questionnaires; General practice
起源于小肠的巨大间质瘤一例
Authors: 姜波, 王舜华, 董建伟, 李晓东, 姜军永
Journal: BMJ (2010)

患者女性,27岁.发热、下腹痛6 d于2009年11月4日入院.患者于入院前6 d始无明显诱因感发热,体温38.5 ℃左右,伴有腹部隐痛,以下腹部为主.体检:体温39 ℃,心肺无异常,中下腹部轻度隆起,可扪及25 cm×20 cm包块,轻度活动,叩诊呈实音,听诊肠鸣音正常.妇科检查:下腹部及盆腔可扪及巨大包块,位于子宫上方,与子宫关系密切。
Hepatocellular carcinoma with ARID1A mutation is associated with higher TMB and poor survival.
Authors: Yaorong Peng, Bowen Gao, Zhenyu Zhou, Tingting Chen, Wenzhuan Xie, Mengli Huang, Wenbin Li
Journal: Journal of Clinical Oncology (2020)

e16667 Background: Hepatocellular carcinoma (HCC) is a heterogeneous disease that lacks molecular predictors of response to available treatments. AT-rich interactive domain 1A (ARID1A), a SWI/SNF chromatin remodeling gene, is commonly mutated in human cancers and hypothesized to be a tumor suppressor gene. In recent years, immune checkpoint blockade immunotherapies (ICIs) are promising therapies for multiple cancers including HCC, and tumor mutation burden (TMB) was an important biomarker to predict the efficacy of ICIs. Besides, previous research reported that ARID1A deficiency was associated with mismatch repair (MMR) in cancer, and may cooperated with ICIs. Methods: Whole exome sequencing data of 10336 pan-cancer patients including 353 HCC patients was obtained from the Cancer Genome Altas (TCGA). Next generation sequencing (NGS) data of 15849 pan-cancer patients including 1926 HCC patients from Chinese clinical dataset were analyzed to explore the correlation between ARID1A gene mutation and TMB. TMB was defined as total number of somatic non-synonymous mutations in coding region. Prognostic data of 136 HCC patients were obtained from the MSK-IMPACT Clinical Sequencing Cohort (MSKCC). Results: In total, 8.62% (891/10336) of pan-cancer patients in TCGA harboring ARID1A mutation and 8.47% (3188/37628) in Chinese cohort, while mutant percentage of HCC was 9.35% (33/353) in TCGA, 9.03% (174/1926) in Chinese cohort, the alternation frequency of ARID1A in two cohorts was no significant difference (P = 0.3334). The medium TMB level of ARID1A mutant group was higher than wild-type group with significant difference both in Chinese pan-cancer and HCC (medium TMB level, P &lt; 0.0001). Results of 18 kinds of ARID1A mutated tumors patients in TCGA cohort indicated that ARID1A mutation was an independent risk factor in liver cancer affecting overall survival (OS, HR 2.43, 95% IC 1.07-5.54, P = 0.0286). Besides, Kaplan-Meier analysis was performed on HCC patients in MSKCC cohort, ARID1A statue resulted in significantly shorter OS (median, 12.2 vs 21.43 months; HR 2.5; P = 0.0092). Conclusions: The results indicated that ARID1A gene mutation was a poor prognostic factor in hepatocellular carcinoma, and these mutational states were associated with higher TMB level, which might be a potential positive biomarker of immunotherapy.
Treatment of chloasma
Authors: 涂彩霞, 白明辉
Journal: BMJ (2007)

黄褐斑也称妊娠斑、肝斑等,中青年女性多见,好发于面颊、前额和上唇部等,呈不规则的棕色或浅灰棕色的色素沉着,日晒后加重.由于黄褐斑具有顽固和复发的特点,故其治疗较困难.治疗的目的通常包括在发生副作用可能性最小的条件下,减轻复发的程度,减少受累面积,改善美容上的缺陷并缩短清除所需的时间[1].治疗原则包括避免紫外线照射、抑制黑素细胞活性或黑素合成、破坏清除黑色素小体[2]。
A Novel TGF-β2/Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β2-Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks
Authors: Benjamin Boyerinas, Sara M. Miller, Ryan C. Murray, John W. Evans, Geoffrey B. Parsons, Katherine J. Seidl, Kevin M. Friedman, Richard A. Morgan
Journal: Blood (2017)
Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey
Authors: 陈亮, 周飞, 李辉, 邢西迁, 韩秀迪, 王一民, 张春晓, 索立俊, 王金祥, 于国华, 王光强, 姚学新, 于红霞, 王蕾, 刘萌, 薛春雪, 刘波, 朱晓莉, 李艳丽, 肖颖, 崔晓静, 李丽娟, M Uyeki Timothy, 王辰, 曹彬, 中国肺炎研究网（CAP-China）
Journal: BMJ (2018)

目的
调查中国社区获得性肺炎（CAP）住院患者的临床特征和管理情况。


设计
一个多中心、回顾性、观察性研究。


地点
从2014年1月1日至12月31日中国北方、中部和南方的13家教学医院。


研究对象
采用标准病例报告表收集所有年龄≥14岁、影像学证实的CAP患者的信息。


主要和次要测量结局
CAP管理过程中的资源消耗。


结果
通过对14 793例患者进行筛选，5 828例影像学证实的CAP患者纳入最终分析。CURB-65评分0~1分和肺炎严重性指数（PSI）分级Ⅰ~Ⅱ级的低死亡风险患者各占81.2% (4 434/5 594)和56.4% (2 034/3 609)。21.7%(1 111/5 130)的患者在住院时已经达到临床稳定。12.7% (738/5 828)的患者获得病原学诊断。40.9% (1 575/3 852)无铜绿假单胞菌感染危险因素的患者接受了过度的经验性抗感染治疗。从临床稳定到出院时间5.0天，30天病死率4.2%。


结论
上述数据证实在中国CAP管理中存在医疗资源过度消耗的现象。同时也表明仍存在改进的空间，并因此可为医疗保健系统节省大量的资源。
Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
Authors: Jorge E. Cortes, Elza Lomaia, Anna Turkina, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Christine Rojas, Charles Chuah, Christopher Kevin Arthur, Jane Apperley, Dong-Wook Kim, Andreas Hochhaus, Philippe H. Rousselot, Gianantonio Rosti, Michael J. Mauro, Jeffrey Howard Lipton, Daniel Naranjo, Guohui Liu, Shouryadeep Srivastava, Michael W.N. Deininger
Journal: Journal of Clinical Oncology (2020)

7502 Background: In PACE (NCT01207440) heavily pretreated patients (pts) with chronic-phase CML (CP-CML) had deep, lasting responses to PON; long-term follow-up showed increasing rates of arterial occlusive events (AOEs). We present IA results from OPTIC (NCT02467270), evaluating the association between PON exposure, efficacy, and safety, and response-based dose reduction in pts with CP-CML. Methods: This ongoing, multicenter, randomized phase 2 trial enrolled pts with CP-CML resistant or intolerant to ≥2 TKIs or with a T315I mutation to receive PON at a starting dose of 45 mg (cohort A), 30 mg (B), and 15 mg (C) qd. Doses were reduced to 15 mg qd on achievement of ≤1% BCR-ABL1 IS in A/B. Primary endpoint: 12 mo ≤1% BCR-ABL1 IS ; secondary endpoints include cytogenetic and molecular response and AOE, VTE, and TEAE rates. Results are descriptive at this IA and will be inferential by adjusting multiplicity across 3 cohorts at final analysis. Results: 283 pts were randomized (A/B/C: n = 94/95/94); median age 48 y (18‒81 y). 26% had hypertension history; 2/43/55% received 1/2/≥3 TKIs; 40% had ≥1 baseline (BL) mutations, with 23% T315I. At IA data cutoff (20 Jul 2019), 162 pts (57%; n = 57/51/54) remained on study treatment. Among 282 pts in the safety population, median duration of exposure was ≈1 y (A/B/C, 12.9/11.2/11.0 mo). At 12 mo, 39% (95% CI, 27.6, 50.6), 27% (17.6, 39.1), and 26% (16.5, 38.6) in A, B, and C, respectively, achieved ≤1% BCR-ABL1 IS . Additional efficacy in Table. Dose reductions due to efficacy (A/B): 35/21%. Most common TEAEs (any grade/≥3): thrombocytopenia 39/27%, neutropenia 25/17%. AOEs/serious AOEs were reported by (A, B, C) 5%/2%, 4%/3%, and 1%/0%. Dose reductions due to TEAEs: (A/B/C): 44/31/28%; discontinuations due to TEAEs: 18/15/14%. There were 4 (1.4%) on-study deaths; A, sudden death, n = 2; C, pneumonia, n = 2; no deaths were due to AOEs. Clinical trial information: NCT01207440 . Conclusions: OPTIC IA shows a trend toward dose-dependent efficacy and safety and may provide a refined understanding of the PON benefit:risk profile and its relation to dose. Data from longer follow-up may support an alternate dosing regimen for pts with CP-CML. [Table: see text]
Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.
Authors: Khalid A Al-Saleh, Adda Bounedjar, Mohammed Oukkal, Hasen Mahfouf, Kamel Bouzid, Assia Bensalem, Prof Taha Fillali, Blaha Larbaoui, Alaa Kandil, Meteb Alfoheidi, Hassan Errihani, Marwan Ghosn, Nashwa A Abdulaziz, Farida Dabouz, Mohun Ranvir K. Bahadoor, Heba Mohamed El Zawahry, Sherif A Kullab, Jean-Marc A. Nabholtz
Journal: Journal of Clinical Oncology (2020)

594 Background: While hormonal therapy (HT) is a fundamental treatment in breast cancer therapy, neoadjuvant NAHT is not considered standard. The SAFIA trial is a prospective international neoadjuvant Phase III investigating the potential role of the addition of palbociclib (P) in patients (pts) sensitive to HT. We report the results of induction Faslodex (+/- zoladex) in pts initially selected by RS &lt; 31, in order to assess their individual HT sensitivity before double-blind randomization HT vs HT + P followed by surgery. Materials and Methods: A total of 308 pts (stages II and IIIA Luminal A/B HER2 negative) in 24 centers and 6 countries (Middle-East/Maghreb) underwent upfront RS to select pts for induction HT. Pts with RS &lt; 31 received induction neoadjuvant fulvestrant (500 mg i.m Day 1, 14, 28 then q.4 weeks) + goseriline (3.6 mg s.c q.4 w for pre and peri-menopausal pts) for 4 months, followed by clinical and radiological assessment of the disease response before randomization. Response was defined as no progression: Complete Response-CR/ Partial Response-PR: &gt; 50% and Minor Response-MR: &lt; 50% to &gt; 0%/ No Response-NR: progression &gt; 0%. Results: A total of 70 pts (22%) with RS &gt; 31 were excluded, leaving 238 eligible pts for NAHT, age (25-84); pre-peri/ post menopause: 135 (57%)/103 (43%); Luminal A/B: 112 (49%)/114 (51%); Stage II/IIIA: 196 (87%) / 29 (13%). One hundred and seventy-seven pts (177) have validated responses to induction NAHT: CR: 9 pts (5%) / MR: 105 pts (59%) for major response rate: 64% / MR: 56 pts (32%) / NR: 7 pts (4%); available RS 0-10: 23 pts (16%) / RS 11-18: 67 pts (47%) / RS 19-25: 34 pts (24%) / RS 26-30: 18 pts (13%). Correlations between Response to NAHT and RS are shown in the table below (not statistically significant). Conclusions: In our population, upfront Oncotype DX RS &lt; 31 allowed to select pts for induction NAHT without loss of chances with a no-progression rate (CR+PR = MR) of 96%. No significant correlation was found between RS and response to NAHT. Upfront RS &gt; 31 (22%) is selecting pts candidates for neoadjuvant chemotherapy with a potential high risk of endocrine resistance. Clinical trial information: ICRG1201 .
Clinical outcomes of MSI-high (MSI-H) versus stable (MSS) endometrial carcinoma (EC) after front-line platinum chemotherapy and subsequent matched therapy.
Authors: Natalie Ngoi, Manavi Sachdeva, Prevathi Haran, Diana Lim, Valerie Heong, Yi Wan Lim, Lim Siew Eng, Kah Wieng Tham, Andrea Wong, Sophia Zhong, Santhiay Nathan, Pearl Tong, Jeffrey Low, Joseph Ng, Ilancheran Arunachalam, David Shao Peng Tan
Journal: Journal of Clinical Oncology (2020)

6086 Background: Precision oncology approaches in EC patients (pts) are evolving with emerging targeted therapy. We reviewed the effect of genomic findings on treatment choice and outcome in an Asian EC cohort. Methods: Recurrent or metastatic ECs were prospectively profiled with next-generation sequencing (NGS) and relevant immunohistochemistry. Clinical data were collected to assess outcomes. Results: Between 12/2014 to 12/2019, 51 Asian EC pts of endometrioid (26/51), serous (7/51), carcinosarcoma (4/51), clear cell (4/51) and mixed (10/51) histology were enrolled. 35/51(69%) of tumors were high grade. The median age at diagnosis was 56 (range 37-77), and the median lines of treatment received was 3 (range 1-8). 45/51(88%) of pts had successful NGS profiling, 31/45(69%) using FoundationOne CDx, and 14/45 (31%) on an in-house platform. Frequent mutations (&gt;20%) occurred in PTEN (60%), PIK3CA (49%), TP53 (46%), ARID1A (27%), CTNNB1 (24%) and KRAS (22%). There were 12/51(24%) MSI-H, 25/51(49%) MSS, and 14/51(27%) MSI-unknown tumors. The 6 mth progression free survival (PFS) rate for MSS versus MSI-H pts treated with front-line carboplatin+paclitaxel (CP) was 83% versus 50% (RR 1.67, fisher’s exact 2-sided p=0.09), with a shorter median PFS after 1st line CP for MSI-H versus MSS pts (median 5.2 mth vs. 8.3 mth, not sig). Upon progression, 29/51(57%) of pts were matched to therapy based on tumor profiles. Of these, 7/29(24%), 13/29(45%) and 9/29(31%) matched to anti-PD1/PD-L1, endocrine therapy and other targeted therapy, respectively. Among 7 MSI-H pts matched to anti-PD1/PD-L1 therapy, median PFS was 14.6 mth (95% CI 0.4-29), and objective response rate was 57%(4/7). In subsequent-line, matching to endocrine therapy (HR 4.3 95% CI 0.95-19.0, p=0.06) or other targeted therapy (HR 5.1, 95% CI 1.1-24.5, p=0.04) was associated with worse PFS compared to anti-PD1/PD-L1 therapy. Despite a short median PFS after front-line CP, median overall survival (OS) was not reached for MSI-H pts, compared to 38 mth (95% CI 30.7-46.0) for MSS and MSI-unknown pts. Conclusions: MSI-H EC pts appear to have shorter PFS to front-line CP chemotherapy compared with MSS pts, but may derive durable responses from immunotherapy in subsequent-line therapy. Early use of immunotherapy in advanced MSI-H EC pts should be considered. Further optimisation of therapy is urgently needed in advanced MSS EC.
Risk factors of peripheral neuropathy in elderly with type 2 diabetes mellitus
Authors: Yingchao Zhang, Zhen Yang, Hua Pan, Na Chen, Li Ma, Chen Wang
Journal: BMJ (2019)

One hundred and sixty-five patients with type 2 diabetes mellitus (T2DM) aged 60 years or older admitted to Beijing Tiantan Hospital from September 2017 to May 2018 were enrolled. There were 90 patients with diabetic peripheral neuropathy (DPN group) and 75 patients without DPN (NDPN group). The clinical data, laboratory tests and other indicators of the two groups were recorded, and the univariate and multivariate logistic analyses were performed. Univariate analysis showed that there was a significant difference in age, duration of diabetes, hemoglobin (Hb), glycosylated hemoglobin (HbA1c), 2-h post-prandial blood glucose (2 hPBG), high-density lipoprotein (HDL-C), treatment compliance and the relation-ship with family members between DPN and NDPN groups (P<0.05). Multivariate regression analysis revealed that the duration of diabetes, HbA1c, HDL-C, Hb and treatment compliance were independent risk factors for DPN in elderly patients with T2DM (P<0.05).


Key words: 
Aged; Diabetes mellitus, type 2; Diabetic neuropathy; Risk factor
腹部恶性黑色素瘤临床及CT表现分析
Authors: 张在鹏, 刘国兵, 廖美焱, 吴光耀, 田志雄
Journal: BMJ (2011)

恶性黑色素瘤常见于皮肤,腹部器官罕见发病,临床表现缺乏特异性[1-2].搜集我院白2001年2月至2008年9月收治的腹部恶性黑色素瘤6例,分析其临床和CT特征,旨在加深临床医生对该病的认识一、临床资料1.一般资料:患者6例,男女各3例. 关键词：黑色素瘤
C型主动脉弓离断一例
Authors: 黄加胜, 黄伟, 徐益民, 柏根基
Journal: BMJ (2012)

患者男,15岁,发作性左侧肢体抖动乏力4年,加重10 d于2010年12月29日门诊查头颅MRI及磁共振血管造影(MRA)示右侧额叶片状异常信号、烟雾病?,入院进一步检查.体检:一般情况良好,体温36.4 ℃,脉搏80次/min,呼吸15次/min;右上肢血压为160/100 mm Hg (21.3/13.3 kPa),左侧脉搏测不到,血压测不到,下肢血压为84/55 mm Hg,四肢肌张力肌力正常. 关键词：心血管畸形